What is Basaglar KwikPen?

Basaglar insulin is a medication containing a recombinant human insulin protein that works in the body as a long-acting parenteral agent to lower blood glucose levels and maintain glycemic control. Basaglar differs slightly from traditional human insulin due to three amino acid types and positions.

The Basaglar Kwikpen is a prefilled delivery device that quickly and easily administers the drug to the patient. The manufacturer is Boehringer Ingelheim.

What is it used for?

Basaglar is used to establish glycemic control in individuals with type 1 or type 2 diabetes mellitus. This product is suitable for use in pediatric patients (>6 years old) with type 1 diabetes mellitus. Basaglar, however, is contraindicated for patients who are hypersensitive to insulin glargine.

How to take Basaglar

Basaglar is administered as a solution for subcutaneous injection once per day. It must be taken at the same time each day. The injection sites of the abdomen, thigh, and deltoid must be rotated from one dose to the next.

Basaglar’s side effects

As with all diabetes-controlling drugs, administration may lead to a low blood sugar condition called hypoglycemia.

Common side effects

  • Low blood sugar
  • Allergic reaction
  • Injection site reactions
  • Skin thickening
  • Pits at the injection site

Severe side effects

  • Hypoglycemia
  • Hypersensitivity
  • Hypokalemia


Basaglar is available as a clear, colorless, sterile solution for injection at 100 units per ml in a 3ml prefilled delivery device, the Basaglar pen


Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.